Additionally, 2 provisional entities, AML with mutated nucleophosmin (NPM1) and AML with mutated CCAAT/enhancer binding protein alpha (CEBPA), have also been recognized [3]. This evidence concerns the gene NPM1 and acute myeloid leukemia.